Date:
Tue, 28 Apr 2026 13:54:27 EDT
Content:
The U.S. Food and Drug Administration (FDA) has published a Form 483 following an inspection of Excel Vision, a pharmaceutical manufacturing facility located in France. The report stems from an evaluation of the facility’s compliance with federal manufacturing standards and quality control protocols.
A Form 483 is issued when FDA investigators observe conditions that may constitute violations of the Food, Drug, and Cosmetic Act. For Excel Vision, the document highlights specific areas of concern identified during the inspection process finalized in late 2024. The company is now required to address these observations and provide a formal response detailing their plan for corrective actions.
Source: FDA Electronic Reading Room
Link:
http://www.fda.gov/drugs/cder-foia-electronic-reading-room/excel-vision-11192024
Keywords:
FDA, Excel Vision, Form 483, France, drug manufacturing, inspectional observations